Infectious disease diagnostics specialist Q-linea AB (STO:QLINEA) announced on Wednesday that it has entered into a worldwide exclusive partnership with Thermo Fisher Scientific Inc (NYSE:TMO), a provider of scientific services, for the commercialisation of ASTar.
ASTar, Q-linea's lead product, is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture.
Under this partnership, Thermo Fisher Scientific will have the exclusive right to offer ASTar to the market in all geographies, with the exception that Q-linea can serve the Swedish market. This partnership is exclusive to both companies regarding fast AST testing.
Also, the two companies will work closely together to provide customers with a comprehensive AST portfolio.
Thermo Scientific Sensititre Complete Automated AST System is the industry standard for traditional MIC determination. Combining Thermo Fisher's tradition, experience and strength in the field, together with Q-linea's unique system for rapid and fully automatic AST analysis is expected to greatly improve and speed up the diagnosis for patients with severe infectious diseases.
Q-linea is a research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval